Protox Therapeutics Inc. (“Protox”, TSX: PRX), a developer of innovative products for the treatment of urological diseases, today announced that it has entered into a US $15 million loan agreement ...
Protox Therapeutics Signs $75 Million License Agreement with Kissei Pharmaceutical Co., Ltd. for Commercialization of PRX302 in Japan for BPH and Prostate Disease VANCOUVER, April 29 /CNW/ - Protox ...
VANCOUVER, Oct. 8 /CNW/ - Protox Therapeutics Inc. (TSX: PRX - News), a leader in the development of receptor targeted fusion proteins, today announced positive 12 month data from its Phase 1 study of ...
For the remainder of the year, Protox expects to continue to incur costs related to the further clinical, manufacturing and regulatory activities associated with its PRX302 BPH program. At June 30, ...
Protox Therapeutics Inc. is appointing William Rohn and Amit Sobti to the company’s board of directors. “We are delighted to welcome Bill and Amit to help guide Protox through the exciting phase of ...
PRX302 is currently in North American Phase II evaluation as PSA-activated pore-punching prodrug. Kissei Pharamaceutical is paying Protox Therapeutics $3 million up front for exclusive Japanese rights ...
Shareholders of Vancouver-based Protox Therapeutics Inc. (TSX:PRX) have approved multi-stage financing that could see a global private equity firm become the company’s majority shareholder. Under the ...
New financing follows on from $9.8M investment made by firm last year. Warburg Pincus made a C$8.3 million (about $8.1 million) investment in Protox Therapeutics as part of a previously agreed ...
It's not easy keeping a poker face. I mean there are so many times when I meet people and it would be beneficial to keep a straight face, but sometimes it's just so hard! When a patient tells me they ...
VANCOUVER – Protox Therapeutics Inc. (TSX:PRX), a developer of drugs to treat urological diseases, said Monday it has entered into a US $15 million loan agreement with a U.S. lender to help the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results